SG10201911351SA - Anti-tau antibodies and methods of use - Google Patents
Anti-tau antibodies and methods of useInfo
- Publication number
- SG10201911351SA SG10201911351SA SG10201911351SA SG10201911351SA SG10201911351SA SG 10201911351S A SG10201911351S A SG 10201911351SA SG 10201911351S A SG10201911351S A SG 10201911351SA SG 10201911351S A SG10201911351S A SG 10201911351SA SG 10201911351S A SG10201911351S A SG 10201911351SA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- tau antibodies
- tau
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2828—Prion diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662431180P | 2016-12-07 | 2016-12-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201911351SA true SG10201911351SA (en) | 2020-02-27 |
Family
ID=60703236
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201911351SA SG10201911351SA (en) | 2016-12-07 | 2017-12-06 | Anti-tau antibodies and methods of use |
Country Status (17)
Country | Link |
---|---|
US (3) | US10711058B2 (zh) |
EP (1) | EP3551220A1 (zh) |
JP (2) | JP7193457B2 (zh) |
KR (2) | KR102587130B1 (zh) |
CN (2) | CN118165104A (zh) |
AR (1) | AR110321A1 (zh) |
AU (1) | AU2017373889A1 (zh) |
CA (1) | CA3044679A1 (zh) |
CR (2) | CR20230163A (zh) |
IL (1) | IL266911B1 (zh) |
MA (1) | MA48595A (zh) |
MX (1) | MX2019006334A (zh) |
PE (2) | PE20191135A1 (zh) |
SG (1) | SG10201911351SA (zh) |
TW (2) | TW202328181A (zh) |
WO (1) | WO2018106781A1 (zh) |
ZA (1) | ZA201903578B (zh) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014165271A2 (en) | 2013-03-13 | 2014-10-09 | Neotope Biosciences Limited | Tau immunotherapy |
PE20180317A1 (es) | 2015-06-05 | 2018-02-09 | Genentech Inc | Anticuerpos anti-tau y metodos de uso |
WO2017191560A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
JP7170316B2 (ja) | 2016-05-02 | 2022-11-14 | プロセナ バイオサイエンシーズ リミテッド | タウ免疫療法 |
CN117820467A (zh) | 2016-12-07 | 2024-04-05 | 基因泰克公司 | 抗tau抗体和使用方法 |
KR102587130B1 (ko) | 2016-12-07 | 2023-10-11 | 제넨테크, 인크. | 항-타우 항체 및 이의 이용 방법 |
MA47499A (fr) | 2017-02-17 | 2019-12-25 | Denali Therapeutics Inc | Anticorps anti-tau et leurs procédés d'utilisation |
WO2018204546A2 (en) | 2017-05-02 | 2018-11-08 | Prothena Biosciences Limited | Antibodies recognizing tau |
AR113792A1 (es) | 2017-10-25 | 2020-06-10 | Janssen Pharmaceuticals Inc | Composiciones de péptidos tau fosforilados y sus usos |
EA202192203A1 (ru) | 2019-02-08 | 2021-10-20 | Ац Иммуне С.А. | СПОСОБ БЕЗОПАСНОГО ВВЕДЕНИЯ ВАКЦИНЫ ФОСФОРИЛИРОВАННОГО ПЕПТИДА Tau |
BR112021016947A2 (pt) | 2019-03-03 | 2021-11-03 | Prothena Biosciences Ltd | Anticorpos que reconhecem tau |
BR112021021213A2 (pt) * | 2019-04-24 | 2021-12-21 | Ac Immune Sa | Administração heteróloga de vacinas de tau |
GB202010652D0 (en) * | 2020-07-10 | 2020-08-26 | Wista Lab Ltd | Anti-tau antibodies |
CN112694532B (zh) * | 2021-01-12 | 2023-04-18 | 倍而达药业(苏州)有限公司 | 抗Siglec-15的抗体或其抗原结合片段及应用 |
AU2022381556A1 (en) * | 2021-11-03 | 2024-05-02 | Eisai R&D Management Co., Ltd. | Anti-tau antibody compositions, dosage forms, and methods |
WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (131)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US5811310A (en) | 1986-09-30 | 1998-09-22 | Albert Einstein College Of Medicine Of Yeshiva Univ. | The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
EP0861893A3 (en) | 1991-09-19 | 1999-11-10 | Genentech, Inc. | High level expression of immunoglobulin polypeptides |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
DE69334255D1 (de) | 1992-02-06 | 2009-02-12 | Novartis Vaccines & Diagnostic | Marker für Krebs und biosynthetisches Bindeprotein dafür |
DE69329503T2 (de) | 1992-11-13 | 2001-05-03 | Idec Pharma Corp | Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma |
CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
EP0994903B1 (en) | 1997-06-24 | 2005-05-25 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
BR9813365A (pt) | 1997-12-05 | 2004-06-15 | Scripps Research Inst | Método para produção e humanização de um anticorpo monoclonal de rato |
ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
DK2180007T4 (da) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
PT1176195E (pt) | 1999-04-09 | 2013-07-18 | Kyowa Hakko Kirin Co Ltd | Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
KR100797667B1 (ko) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | 외래 유전자의 전사를 조절하는 방법 |
AU7950400A (en) | 1999-10-19 | 2001-04-30 | Kyowa Hakko Kogyo Co. Ltd. | Process for producing polypeptide |
CA2393869A1 (en) | 1999-12-15 | 2001-06-21 | Genetech,Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
DK2857516T3 (en) | 2000-04-11 | 2017-08-07 | Genentech Inc | Multivalent antibodies and uses thereof |
EP3263702A1 (en) | 2000-10-06 | 2018-01-03 | Kyowa Hakko Kirin Co., Ltd. | Cells producing antibody compositions |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
KR100857943B1 (ko) | 2000-11-30 | 2008-09-09 | 메다렉스, 인코포레이티드 | 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류 |
EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
AT500379B8 (de) | 2001-02-02 | 2009-08-15 | Axon Neuroscience | Tau-proteine |
MXPA04001072A (es) | 2001-08-03 | 2005-02-17 | Glycart Biotechnology Ag | Variantes de glicosilacion de anticuerpos que tienen citotoxicidad celulares dependiente de anticuerpos incrementada. |
KR100988949B1 (ko) | 2001-10-25 | 2010-10-20 | 제넨테크, 인크. | 당단백질 조성물 |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
DE60336548D1 (de) | 2002-04-09 | 2011-05-12 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
US20050031613A1 (en) | 2002-04-09 | 2005-02-10 | Kazuyasu Nakamura | Therapeutic agent for patients having human FcgammaRIIIa |
EP1498491A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA |
EP1500400A4 (en) | 2002-04-09 | 2006-10-11 | Kyowa Hakko Kogyo Kk | MEDICAMENT WITH ANTIBODY COMPOSITION |
EP1498490A4 (en) | 2002-04-09 | 2006-11-29 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING ANTIBODY COMPOSITION |
PL373256A1 (en) | 2002-04-09 | 2005-08-22 | Kyowa Hakko Kogyo Co, Ltd. | Cells with modified genome |
JP4753578B2 (ja) | 2002-06-03 | 2011-08-24 | ジェネンテック, インコーポレイテッド | 合成抗体ファージライブラリー |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
SI2289936T1 (sl) | 2002-12-16 | 2017-10-30 | Genentech, Inc. | Imunoglobulinske variante in njihove uporabe |
WO2004058239A1 (en) | 2002-12-24 | 2004-07-15 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
AU2004205631A1 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
WO2005035586A1 (ja) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | 融合蛋白質組成物 |
AU2004280065A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase |
LT2380911T (lt) | 2003-11-05 | 2018-07-10 | Roche Glycart Ag | Antigeną surišančios molekulės, pasižyminčios padidintu fc receptoriaus surišimo afiniškumu ir efektoriaus funkcija |
WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
EP2360186B1 (en) | 2004-04-13 | 2017-08-30 | F. Hoffmann-La Roche AG | Anti-P-selectin antibodies |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
PL1791565T3 (pl) | 2004-09-23 | 2016-10-31 | Modyfikowane cysteiną przeciwciała i koniugaty | |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
EP1957531B1 (en) | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
EP1973951A2 (en) | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
JP2009536527A (ja) | 2006-05-09 | 2009-10-15 | ジェネンテック・インコーポレーテッド | 最適化されたスキャフォールドを備えた結合ポリペプチド |
EP2471816A1 (en) | 2006-08-30 | 2012-07-04 | Genentech, Inc. | Multispecific antibodies |
GB0624500D0 (en) | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
EP2235064B1 (en) | 2008-01-07 | 2015-11-25 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
UA107571C2 (xx) | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
EP3960865A1 (en) | 2010-08-02 | 2022-03-02 | Regeneron Pharmaceuticals, Inc. | Mice that make binding proteins comprising vl domains |
ES2548686T3 (es) * | 2010-10-07 | 2015-10-20 | Ac Immune S.A. | Anticuerpos que reconocen fosfo-Tau |
US8940272B2 (en) | 2010-10-11 | 2015-01-27 | University Of Zurich | Human anti-tau antibodies |
EP2654790B1 (en) | 2010-12-22 | 2019-02-06 | Teva Pharmaceuticals Australia Pty Ltd | Modified antibody with improved half-life |
CA2826286C (en) | 2011-01-31 | 2021-09-21 | Intellect Neurosciences Inc. | Treatment of tauopathies |
GB201112056D0 (en) | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
EP2758433B1 (en) | 2011-09-19 | 2017-10-18 | Axon Neuroscience SE | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
US9540434B2 (en) * | 2011-10-07 | 2017-01-10 | Ac Immune S.A. | Phosphospecific antibodies recognising tau |
EP3578567A1 (en) * | 2011-12-20 | 2019-12-11 | Janssen Biotech, Inc. | Anti-phf-tau antibodies and their uses |
MX356800B (es) * | 2012-04-05 | 2018-06-13 | Ac Immune Sa | Anticuerpo tau humanizado. |
SG11201408626YA (en) | 2012-07-03 | 2015-03-30 | Univ Washington | Antibodies to tau |
PT2885010T (pt) | 2012-08-16 | 2020-03-11 | Ipierian Inc | Métodos de tratamento de uma tauopatia |
EP2887955B1 (en) | 2012-08-21 | 2020-08-19 | Institute for Molecular Medicine, Inc. | Compositions and methods related to diseases associated with deposits of amyloid, tau, and alpha-synuclein |
US20140056901A1 (en) | 2012-08-21 | 2014-02-27 | The Institute For Molecular Medicine | Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies |
JP6324974B2 (ja) | 2012-10-12 | 2018-05-23 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ | タウの毒性オリゴマー形態を特異的に認識する抗体ベースの試薬 |
KR102234324B1 (ko) * | 2012-12-21 | 2021-03-31 | 바이오젠 엠에이 인코포레이티드 | 인간 항-타우 항체 |
US9039633B2 (en) | 2012-12-24 | 2015-05-26 | Transmed7, Llc | Automated, selectable, soft tissue excision biopsy devices and methods |
US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
WO2014165271A2 (en) | 2013-03-13 | 2014-10-09 | Neotope Biosciences Limited | Tau immunotherapy |
CN105143258B (zh) | 2013-03-15 | 2020-06-23 | Ac免疫有限公司 | 抗Tau抗体和使用方法 |
JP6446443B2 (ja) | 2013-06-10 | 2018-12-26 | アイピエリアン,インコーポレイティド | タウオパチーの処置方法 |
EP3074420A2 (en) | 2013-11-27 | 2016-10-05 | Ipierian, Inc. | Methods of treating a tauopathy |
MX2016007208A (es) | 2013-12-20 | 2016-07-21 | Hoffmann La Roche | Anticuerpos anti-tau(ps422) humanizados y metodos de uso. |
EP3104870A4 (en) | 2014-02-14 | 2017-09-13 | Ipierian, Inc. | Tau peptides, anti-tau antibodies, and methods of use thereof |
TWI664190B (zh) | 2014-06-27 | 2019-07-01 | 美商C2N醫療診斷有限責任公司 | 人類化抗-tau抗體 |
US10098973B2 (en) | 2014-10-10 | 2018-10-16 | National Research Council Of Canada | Anti-tau antibody and uses thereof |
US10323082B2 (en) | 2014-10-14 | 2019-06-18 | The Research Foundation For Mental Hygiene, Inc. | Treatment of tauopathies by passive immunization targeting the N-terminal projection domain of tau |
CA2874083C (en) | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
WO2016137950A1 (en) | 2015-02-24 | 2016-09-01 | Rpeptide, Llc | Anti-tau antibodies |
TWI669314B (zh) | 2015-02-26 | 2019-08-21 | 美國禮來大藥廠 | 針對tau之抗體及其用途 |
PE20180317A1 (es) * | 2015-06-05 | 2018-02-09 | Genentech Inc | Anticuerpos anti-tau y metodos de uso |
US20200030445A1 (en) | 2015-06-12 | 2020-01-30 | C2N Diagnostics, Llc | Stable formulations of humanized anti-tau antibody |
WO2017005734A1 (en) | 2015-07-06 | 2017-01-12 | Ucb Biopharma Sprl | Tau-binding antibodies |
CA2991264C (en) | 2015-07-06 | 2023-10-10 | Ucb Biopharma Sprl | Tau-binding antibodies |
JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
WO2017189963A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
WO2017191560A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
CN116041504A (zh) | 2016-07-12 | 2023-05-02 | H.隆德贝克有限公司 | 特异性针对过度磷酸化τ蛋白的抗体及其使用方法 |
CN117820467A (zh) | 2016-12-07 | 2024-04-05 | 基因泰克公司 | 抗tau抗体和使用方法 |
KR102587130B1 (ko) | 2016-12-07 | 2023-10-11 | 제넨테크, 인크. | 항-타우 항체 및 이의 이용 방법 |
EP3601337A1 (en) | 2017-03-28 | 2020-02-05 | Genentech, Inc. | Methods of treating neurodegenerative diseases |
-
2017
- 2017-12-06 KR KR1020197016226A patent/KR102587130B1/ko active IP Right Grant
- 2017-12-06 JP JP2019530098A patent/JP7193457B2/ja active Active
- 2017-12-06 MA MA048595A patent/MA48595A/fr unknown
- 2017-12-06 KR KR1020237033931A patent/KR20230146126A/ko active Application Filing
- 2017-12-06 SG SG10201911351SA patent/SG10201911351SA/en unknown
- 2017-12-06 CR CR20230163A patent/CR20230163A/es unknown
- 2017-12-06 AR ARP170103417A patent/AR110321A1/es unknown
- 2017-12-06 MX MX2019006334A patent/MX2019006334A/es unknown
- 2017-12-06 EP EP17817624.4A patent/EP3551220A1/en active Pending
- 2017-12-06 CN CN202410021983.0A patent/CN118165104A/zh active Pending
- 2017-12-06 AU AU2017373889A patent/AU2017373889A1/en active Pending
- 2017-12-06 PE PE2019001208A patent/PE20191135A1/es unknown
- 2017-12-06 IL IL266911A patent/IL266911B1/en unknown
- 2017-12-06 TW TW111145043A patent/TW202328181A/zh unknown
- 2017-12-06 PE PE2020001317A patent/PE20201186A1/es unknown
- 2017-12-06 TW TW106142639A patent/TWI787219B/zh active
- 2017-12-06 CN CN201780075563.9A patent/CN110290801B/zh active Active
- 2017-12-06 CR CR20190271A patent/CR20190271A/es unknown
- 2017-12-06 WO PCT/US2017/064869 patent/WO2018106781A1/en unknown
- 2017-12-06 CA CA3044679A patent/CA3044679A1/en active Pending
-
2019
- 2019-05-23 US US16/420,673 patent/US10711058B2/en active Active
- 2019-06-04 ZA ZA2019/03578A patent/ZA201903578B/en unknown
-
2020
- 2020-06-05 US US16/893,678 patent/US11427629B2/en active Active
-
2022
- 2022-06-22 US US17/846,302 patent/US20230043289A1/en active Pending
- 2022-12-08 JP JP2022196074A patent/JP2023051929A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3551220A1 (en) | 2019-10-16 |
IL266911A (en) | 2019-07-31 |
CR20230163A (es) | 2023-07-06 |
PE20201186A1 (es) | 2020-11-03 |
WO2018106781A1 (en) | 2018-06-14 |
US20230043289A1 (en) | 2023-02-09 |
CN118165104A (zh) | 2024-06-11 |
KR102587130B1 (ko) | 2023-10-11 |
US20210122811A1 (en) | 2021-04-29 |
ZA201903578B (en) | 2020-12-23 |
IL266911B1 (en) | 2024-06-01 |
JP2020511938A (ja) | 2020-04-23 |
KR20190091274A (ko) | 2019-08-05 |
PE20191135A1 (es) | 2019-09-02 |
US11427629B2 (en) | 2022-08-30 |
JP7193457B2 (ja) | 2022-12-20 |
US20200017579A1 (en) | 2020-01-16 |
CR20190271A (es) | 2019-09-03 |
CN110290801B (zh) | 2024-01-26 |
US10711058B2 (en) | 2020-07-14 |
TW201821438A (zh) | 2018-06-16 |
AU2017373889A1 (en) | 2019-06-06 |
JP2023051929A (ja) | 2023-04-11 |
KR20230146126A (ko) | 2023-10-18 |
MX2019006334A (es) | 2019-08-01 |
AR110321A1 (es) | 2019-03-20 |
CN110290801A (zh) | 2019-09-27 |
MA48595A (fr) | 2020-03-18 |
TW202328181A (zh) | 2023-07-16 |
TWI787219B (zh) | 2022-12-21 |
CA3044679A1 (en) | 2018-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201907054B (en) | Anti-tau antibodies and methods of use | |
IL265800A (en) | Anti-lag-3 antibodies and methods of using them | |
IL268658A (en) | Anti-tau antibodies and methods of use thereof | |
ZA201903578B (en) | Anti-tau antibodies and methods of use | |
HK1249445A1 (zh) | 抗分揀蛋白抗體和其使用方法 | |
IL259495A (en) | Antibodies and methods for using them | |
HK1252698A1 (zh) | 抗siglec-9抗體及其使用方法 | |
SG10201912879YA (en) | Anti-sirp-alpha antibodies and methods of use thereof | |
HK1247569A1 (zh) | 抗pvrig抗體和使用方法 | |
SG10201912563XA (en) | Anti-tim-3 antibodies and methods of use thereof | |
HK1252696A1 (zh) | 抗siglec-7抗體及其使用方法 | |
SG10201912150TA (en) | Anti-trem2 antibodies and methods of use thereof | |
IL266913A (en) | Anti-tau antibodies and methods of using them | |
EP3310378C0 (en) | ANTI-CLL-1 ANTIBODIES AND METHOD OF USE | |
ZA202001985B (en) | Anti-htra1 antibodies and methods of use thereof | |
IL265957A (en) | Anti-c1s antibodies and methods of using them |